Skip to main content
ABION Inc. logo

ABION Inc. — Investor Relations & Filings

Ticker · 203400 ISIN · KR7203400007 KO Professional, scientific and technical activities
Open in API
Filings indexed 409 across all filing types
Latest filing 2020-08-03 Capital/Financing Update
Country KR South Korea
Listing KO 203400

About ABION Inc.

https://abionbio.com/en/

ABION Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative medicines, focusing on first-in-class and best-in-class therapeutics for oncology and viral diseases. The company's lead oncology asset is ABN401, a selective c-Met tyrosine kinase inhibitor (TKI) designed to treat non-small cell lung cancer (NSCLC) with MET mutations, which has shown a favorable safety profile. Another key pipeline candidate is ABN501, a novel monoclonal antibody targeting Claudin-3 for various cancers. Beyond oncology, ABION is developing ABN101, a second-generation Interferon-β formulated as a broad-spectrum anti-viral inhaler for respiratory infections. The company aims to commercialize its assets in global markets through internationally recognized clinical processes.

Recent filings

Filing Released Lang Actions
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Report' (주요사항보고서) filed with the Financial Supervisory Service/Korea Exchange regarding the issuance of convertible bonds (전환사채권 발행결정). It details the terms of the bond, including interest rates, conversion prices, maturity dates, and the use of proceeds. This type of regulatory filing for capital structure changes, specifically debt issuance, falls under the 'Capital/Financing Update' category.
2020-08-03 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea (often referred to as the 5% rule filing). It details changes in share ownership by a major shareholder (Telcon RF Pharmaceutical) in the issuer (Abion Co., Ltd.). This falls under the category of Major Shareholding Notification.
2020-07-03 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service (FSS) in South Korea. This type of filing is a mandatory disclosure for major shareholders (10% or more) or executives to report changes in their shareholdings. In the context of the provided categories, this falls under 'Major Shareholding Notification' (MRQ) as it details the acquisition of shares by a major shareholder (Telcon RF Pharmaceutical) in the issuer (Abion Co., Ltd.).
2020-07-03 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is explicitly labeled as a '정정신고' (Correction Report). It details changes to stock option grants, including the number of shares and the list of recipients. In the context of Korean regulatory filings (DART), this type of disclosure regarding capital structure and equity-based compensation falls under general regulatory filings that do not fit into specific categories like M&A or dividends, and it is not a report publication announcement. Therefore, it is classified as a Regulatory Filing (RNS).
2020-06-12 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '정정신고(보고)' (Correction Report) regarding '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options). It details specific changes to the number of shares granted and the status of recipients (directors/employees). Since this is a specific regulatory disclosure regarding stock options and capital-related adjustments that does not fit into the other categories like 10-K or IR, it is classified as a Regulatory Filing (RNS).
2020-06-12 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. This document tracks changes in share ownership (crossing the 5% threshold) and is filed with the Financial Supervisory Service (FSS). It does not fit into categories like 10-K, Earnings Release, or Investor Presentation. Since it is a specific regulatory disclosure regarding major shareholding changes, it falls under the 'Major Shareholding Notification' category.
2020-06-04 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.